Literature DB >> 23318930

Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration.

Mareike Caesar1, Susanne Zach, Coby B Carlson, Kathrin Brockmann, Thomas Gasser, Frank Gillardon.   

Abstract

Recent studies indicate that the Parkinson's disease-linked leucine-rich repeat kinase 2 (LRRK2) modulates cytoskeletal functions by regulating actin and tubulin dynamics, thereby affecting neurite outgrowth. By interactome analysis we demonstrate that the binding of LRRK2 to tubulins is significantly enhanced by pharmacological LRRK2 inhibition in cells. Co-incubation of LRRK2 with microtubules increased the LRRK2 GTPase activity in a cell-free assay. Destabilization of microtubules causes a rapid decrease in cellular LRRK2(S935) phosphorylation indicating a decreased LRRK2 kinase activity. Moreover, both human LRRK2(G2019S) fibroblasts and mouse LRRK2(R1441G) fibroblasts exhibit alterations in cell migration in culture. Treatment of mouse fibroblasts with the selective LRRK2 inhibitor LRRK2-IN1 reduces cell motility. These findings suggest that LRRK2 and microtubules mutually interact both in non-neuronal cells and in neurons, which might contribute to our understanding of its pathogenic effects in Parkinson's disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318930     DOI: 10.1016/j.nbd.2012.12.019

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  30 in total

Review 1.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 2.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 3.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

Review 4.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

5.  The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Authors:  Mark S Moehle; João Paulo Lima Daher; Travis D Hull; Ravindra Boddu; Hisham A Abdelmotilib; James Mobley; George T Kannarkat; Malú G Tansey; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-29       Impact factor: 6.150

6.  Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.

Authors:  Matthew Hamm; Rachel Bailey; Gerry Shaw; Shu-Hui Yen; Jada Lewis; Benoit I Giasson
Journal:  J Neurosci Res       Date:  2015-06-30       Impact factor: 4.164

7.  Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.

Authors:  Jason Schapansky; Saurabh Khasnavis; Mark P DeAndrade; Jonathan D Nardozzi; Samuel R Falkson; Justin D Boyd; John B Sanderson; Tim Bartels; Heather L Melrose; Matthew J LaVoie
Journal:  Neurobiol Dis       Date:  2017-12-12       Impact factor: 5.996

8.  14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Authors:  Nicholas J Lavalley; Sunny R Slone; Huiping Ding; Andrew B West; Talene A Yacoubian
Journal:  Hum Mol Genet       Date:  2015-11-05       Impact factor: 6.150

9.  LRRK2 and mitochondria: Recent advances and current views.

Authors:  Alpana Singh; Lianteng Zhi; Hui Zhang
Journal:  Brain Res       Date:  2018-06-09       Impact factor: 3.252

10.  LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.

Authors:  Insup Choi; Beomsue Kim; Ji-Won Byun; Sung Hoon Baik; Yun Hyun Huh; Jong-Hyeon Kim; Inhee Mook-Jung; Woo Keun Song; Joo-Ho Shin; Hyemyung Seo; Young Ho Suh; Ilo Jou; Sang Myun Park; Ho Chul Kang; Eun-Hye Joe
Journal:  Nat Commun       Date:  2015-09-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.